Investment Thesis
QuidelOrtho is unprofitable with negative operating cash flow (-33M), declining revenue (-1.9% YoY), and material cash burn (FCF -67M). Elevated debt burden (1.33x D/E, 2.5B LT debt) combined with negative fundamentals creates significant financial stress with limited runway at current burn rates.
Strengths
- Solid asset base of 5.6B with meaningful equity cushion of 1.9B
- Adequate current ratio of 1.43x provides near-term operating flexibility
- EPS improved 45.4% YoY suggesting trajectory from losses toward breakeven
Risks
- Persistent operating losses (-31.8M operating income) with negative FCF (-67M) signals structural profitability challenges
- Revenue contraction of 1.9% YoY indicates declining market demand or market share losses in diagnostics segment
- High leverage (1.33x D/E) with negative cash generation creates unsustainable debt service risk; ~2 year cash runway at current burn rate
- Quick ratio of 0.80x signals liquidity constraints beyond operating liabilities
Key Metrics to Watch
- Operating cash flow trend and path to positive cash generation
- Revenue growth stabilization and gross margin recovery
- Debt reduction progress and refinancing sustainability
Financial Metrics
Revenue
619.8M
Net Income
-91.8M
EPS (Diluted)
$-1.35
Free Cash Flow
-67.0M
Total Assets
5.6B
Cash
140.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-5.1%
Net Margin
-14.8%
ROE
-5.0%
ROA
-1.6%
FCF Margin
-10.8%
Balance Sheet & Liquidity
Current Ratio
1.43x
Quick Ratio
0.80x
Debt/Equity
1.33x
Debt/Assets
67.1%
Interest Coverage
N/A
Long-term Debt
2.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:18:54.122212 |
Data as of: 2026-03-29 |
Powered by Claude AI